Cancer Institute of New Jersey (CINJ), Pediatric Hematology/Oncology

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Precursor Cell Lymphoblastic Leukemia-Lymphoma Medicine & Life Sciences
Methotrexate Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Folic Acid Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1991 2018

1 Citations

An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001

Kahn, J. M., Cole, P., Blonquist, T. M., Stevenson, K., Jin, Z., Barrera, S., Davila, R., Roberts, E., Neuberg, D. S., Athale, U. H., Clavell, L. A., Laverdiere, C., Leclerc, J. M., Michon, B., Schorin, M. A., Welch, J. J. G., Sallan, S. E., Silverman, L. B. & Kelly, K. M., Mar 1 2018, In : Pediatric Blood and Cancer. 65, 3, e26871.

Rutgers, The State University

Research output: Contribution to journalArticle

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hispanic Americans
Survival
Neoplasms
Disease-Free Survival

Association of Combined Modality Therapy vs Chemotherapy Alone with Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma

Jhawar, S. R., Rivera-Núñez, Z., Drachtman, R., Cole, P., Hoppe, B. S. & Parikh, R., Jan 1 2018, (Accepted/In press) In : JAMA Oncology.

Rutgers, The State University

Research output: Contribution to journalArticle

Combined Modality Therapy
Hodgkin Disease
Pediatrics
Drug Therapy
Survival
2 Citations

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

Cole, P., McCarten, K. M., Pei, Q., Spira, M., Metzger, M. L., Drachtman, R., Horton, T. M., Bush, R., Blaney, S. M., Weigel, B. J. & Kelly, K. M., Sep 1 2018, In : The Lancet Oncology. 19, 9, p. 1229-1238 10 p.

Rutgers, The State University

Research output: Contribution to journalArticle

gemcitabine
Hodgkin Disease
Young Adult
Pediatrics
Recurrence